Featured News

There are more exciting opportunities than ever before to participate in celiac disease clinical trials. Researchers are making groundbreaking progress in the race for better treatments with promising new drug candidates. To bring these treatments to market, we need your help. The biggest obstacle in getting a celiac disease drug to market is recruiting enough…

The FDA hosted the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI (GREAT VI) Workshop on Celiac Disease - the second workshop ever held by the FDA for celiac disease.

Periodically, the FDA hosts workshops to help researchers understand exactly what the FDA will be looking for (aka “endpoints”) when evaluating the efficacy of a proposed drug.

ZED1227, an experimental drug was found to be able to prevent intestinal damage in a preliminary trial of 163 adults with celiac disease.

The overall prevalence of celiac disease was found to be 1.6% - a much greater percentage than the 1% that researchers have been approximating for years.

Cabinet Health, a verified gluten-free OTC medicine company, announced their partnership with the Celiac Disease Foundation in order to better support the needs of the celiac community.

A recent study published in JAMA Network, using two decades worth of dietary data, concluded that gluten consumption in people without celiac disease did not impair cognitive function.

Each year, we look forward to May Celiac Awareness Month for the chance to celebrate our community’s tireless work.

The CeDLara Study is for adults who have been diagnosed with celiac disease and are still experiencing symptoms despite following a gluten-free diet.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.